autologous CMV pp65/total tumor mRNA-loaded lipid particle vaccine

An mRNA-based, personalized cancer vaccine consisting of total tumor RNA (TTRNA) derived and amplified from autologous tumor cells, which includes the mRNA encoding the human cytomegalovirus (CMV) matrix protein pp65 (65 kDa lower matrix phosphoprotein; UL83), formulated in lipid particles (LPs), with potential immunostimulatory and antineoplastic activities. Upon administration of the autologous CMV pp65/total tumor mRNA-loaded LP vaccine, the mRNA is taken up, translated and presented by antigen presenting cells (APCs), mainly dendritic cells (DCs). This leads to an induction of cytotoxic T-lymphocyte immune responses that specifically target and destroy the patient's cancer cells that express these tumor antigens. The CMV pp65 protein is the primary component of the enveloped subviral particle of CMV and is expressed in certain tumor types.